These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 25101565)
21. Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience. Levard A; Derbel O; Méeus P; Ranchère D; Ray-Coquard I; Blay JY; Cassier PA BMC Cancer; 2013 Mar; 13():109. PubMed ID: 23496996 [TBL] [Abstract][Full Text] [Related]
22. A Study of Angiogenesis Markers in Patients with Renal Cell Carcinoma Undergoing Therapy with Sunitinib. Stubbs C; Bardoli AD; Afshar M; Pirrie S; Miscoria M; Wheeley I; Porfiri E Anticancer Res; 2017 Jan; 37(1):253-259. PubMed ID: 28011500 [TBL] [Abstract][Full Text] [Related]
23. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients. Vetsika EK; Koinis F; Gioulbasani M; Aggouraki D; Koutoulaki A; Skalidaki E; Mavroudis D; Georgoulias V; Kotsakis A J Immunol Res; 2014; 2014():659294. PubMed ID: 25436215 [TBL] [Abstract][Full Text] [Related]
24. Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma. Liu XD; Hoang A; Zhou L; Kalra S; Yetil A; Sun M; Ding Z; Zhang X; Bai S; German P; Tamboli P; Rao P; Karam JA; Wood C; Matin S; Zurita A; Bex A; Griffioen AW; Gao J; Sharma P; Tannir N; Sircar K; Jonasch E Cancer Immunol Res; 2015 Sep; 3(9):1017-29. PubMed ID: 26014097 [TBL] [Abstract][Full Text] [Related]
25. Endothelial follicle stimulating hormone receptor in primary kidney cancer correlates with subsequent response to sunitinib. Siraj MA; Pichon C; Radu A; Ghinea N J Cell Mol Med; 2012 Sep; 16(9):2010-6. PubMed ID: 22129368 [TBL] [Abstract][Full Text] [Related]
26. Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. Martin-Broto J; Stacchiotti S; Lopez-Pousa A; Redondo A; Bernabeu D; de Alava E; Casali PG; Italiano A; Gutierrez A; Moura DS; Peña-Chilet M; Diaz-Martin J; Biscuola M; Taron M; Collini P; Ranchere-Vince D; Garcia Del Muro X; Grignani G; Dumont S; Martinez-Trufero J; Palmerini E; Hindi N; Sebio A; Dopazo J; Dei Tos AP; LeCesne A; Blay JY; Cruz J Lancet Oncol; 2019 Jan; 20(1):134-144. PubMed ID: 30578023 [TBL] [Abstract][Full Text] [Related]
27. Regorafenib in advanced solitary fibrous tumour: Results from an exploratory phase II clinical study. Stacchiotti S; Baldi GG; Frezza AM; Morosi C; Greco FG; Collini P; Barisella M; Dagrada GP; Zaffaroni N; Pasquali S; Gronchi A; Huang P; Ingrosso M; Tinè G; Miceli R; Casali PG Eur J Cancer; 2023 Dec; 195():113391. PubMed ID: 37918286 [TBL] [Abstract][Full Text] [Related]
29. Suppression of immune regulatory cells with combined therapy of celecoxib and sunitinib in renal cell carcinoma. Zhao Q; Guo J; Wang G; Chu Y; Hu X Oncotarget; 2017 Jan; 8(1):1668-1677. PubMed ID: 27926489 [TBL] [Abstract][Full Text] [Related]
30. Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. van Cruijsen H; van der Veldt AA; Vroling L; Oosterhoff D; Broxterman HJ; Scheper RJ; Giaccone G; Haanen JB; van den Eertwegh AJ; Boven E; Hoekman K; de Gruijl TD Clin Cancer Res; 2008 Sep; 14(18):5884-92. PubMed ID: 18794101 [TBL] [Abstract][Full Text] [Related]
31. In vivo imaging of tumor physiological, metabolic, and redox changes in response to the anti-angiogenic agent sunitinib: longitudinal assessment to identify transient vascular renormalization. Matsumoto S; Saito K; Takakusagi Y; Matsuo M; Munasinghe JP; Morris HD; Lizak MJ; Merkle H; Yasukawa K; Devasahayam N; Suburamanian S; Mitchell JB; Krishna MC Antioxid Redox Signal; 2014 Sep; 21(8):1145-55. PubMed ID: 24597714 [TBL] [Abstract][Full Text] [Related]
32. Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics. Stacchiotti S; Tortoreto M; Bozzi F; Tamborini E; Morosi C; Messina A; Libertini M; Palassini E; Cominetti D; Negri T; Gronchi A; Pilotti S; Zaffaroni N; Casali PG Clin Cancer Res; 2013 Sep; 19(18):5192-201. PubMed ID: 23888069 [TBL] [Abstract][Full Text] [Related]
33. Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour. Stacchiotti S; Saponara M; Frapolli R; Tortoreto M; Cominetti D; Provenzano S; Negri T; Dagrada GP; Gronchi A; Colombo C; Vincenzi B; Badalamenti G; Zuco V; Renne SL; Collini P; Morosi C; Dei Tos AP; Bello E; Pilotti S; Casali PG; D'Incalci M; Zaffaroni N Eur J Cancer; 2017 May; 76():84-92. PubMed ID: 28284173 [TBL] [Abstract][Full Text] [Related]
34. Localization of sunitinib, its metabolites and its target receptors in tumour-bearing mice: a MALDI-MS imaging study. Torok S; Vegvari A; Rezeli M; Fehniger TE; Tovari J; Paku S; Laszlo V; Hegedus B; Rozsas A; Dome B; Marko-Varga G Br J Pharmacol; 2015 Feb; 172(4):1148-63. PubMed ID: 25363319 [TBL] [Abstract][Full Text] [Related]